Review article

Vitamin D deficiency and depression in adults: systematic review and meta-analysis

Rebecca E. S. Anglin, Zainab Samaan, Stephen D. Walter and Sarah D. McDonald

Background
There is conflicting evidence about the relationship between vitamin D deficiency and depression, and a systematic assessment of the literature has not been available.

Aims
To determine the relationship, if any, between vitamin D deficiency and depression.

Method
A systematic review and meta-analysis of observational studies and randomised controlled trials was conducted.

Results
One case–control study, ten cross-sectional studies and three cohort studies with a total of 31,424 participants were analysed. Lower vitamin D levels were found in people with depression compared with controls (SMD = 0.60, 95% CI 0.23–0.97) and there was an increased odds ratio of depression for the lowest v. highest vitamin D categories in the cross-sectional studies (OR = 1.31, 95% CI 1.0–1.71). The cohort studies showed a significantly increased hazard ratio of depression for the lowest v. highest vitamin D categories (HR = 2.21, 95% CI 1.40–3.49).

Conclusions
Our analyses are consistent with the hypothesis that low vitamin D concentration is associated with depression, and highlight the need for randomised controlled trials of vitamin D for the prevention and treatment of depression to determine whether this association is causal.

Declaration of interest
None.

Depression is associated with significant disability, mortality and healthcare costs. It is the third leading cause of disability in high-income countries, and affects approximately 840 million people worldwide. Although biological, psychological and environmental theories have been advanced, the underlying pathophysiology of depression remains unknown and it is probable that several different mechanisms are involved. Vitamin D is a unique neurosteroid hormone that may have an important role in the development of depression. Receptors for vitamin D are present on neurons and glia in many areas of the brain including the cingulate cortex and hippocampus, which have been implicated in the pathophysiology of depression.

Vitamin D is involved in numerous brain processes including neuroimmunomodulation, regulation of neurotrophic factors, neuroprotection, neuroplasticity and brain development, making it biologically plausible that this vitamin might be associated with depression and that its supplementation might play an important part in the treatment of depression. Over two-thirds of the populations of the USA and Canada have suboptimal levels of vitamin D.

Some studies have demonstrated a strong relationship between vitamin D and depression, whereas others have shown no relationship. To date there have been eight narrative reviews on this topic, with the majority of reviews reporting that there is insufficient evidence for an association between vitamin D and depression. None of these reviews used a comprehensive search strategy, provided inclusion or exclusion criteria, assessed risk of bias or combined study findings. In addition, several recent studies were not included in these reviews. Therefore, we undertook a systematic review and meta-analysis to investigate whether vitamin D deficiency is associated with depression in adults in case–control and cross-sectional studies; whether vitamin D deficiency increases the risk of developing depression in cohort studies in adults; and whether vitamin D supplementation improves depressive symptoms in adults with depression compared with placebo, or prevents depression compared with placebo, in healthy adults in randomised controlled trials (RCTs).

Method
We searched the databases MEDLINE, EMBASE, PsycINFO, CINAHL, AMED and Cochrane CENTRAL (up to 2 February 2011) using separate comprehensive strategies developed in consultation with an experienced research librarian (see online supplement DS1). A separate search of PubMed identified articles published electronically prior to print publication within 6 months of our search and therefore not available through MEDLINE. The clinical trials registries clinicaltrials.gov and Current Controlled Trials (controlled-trials.com) were searched for unpublished data. The reference lists of identified articles were reviewed for additional studies.

Eligibility criteria
The following study designs were included: RCTs, case–control studies, cross-sectional studies and cohort studies. All studies enrolled adults (age 18 years) and reported depression as the outcome of interest and vitamin D measurements as a risk factor or intervention. Cross-sectional and cohort studies were required to report depression outcomes for participants with vitamin D deficiency (as defined by each study, see Tables 1 and 2) compared with those with normal vitamin D levels. There was no language restriction. Eligibility criteria are detailed in online supplement DS2.

Outcome
Our primary outcome for all studies was depression diagnosed using one of the following:
(a) a standardised psychiatric interview for the DSM diagnoses of depressive disorders (e.g. the Structured Clinical Interview for DSM Disorders) or ICD diagnoses of a depressive episode or
depression (e.g., the Composite International Diagnostic Interview); 22,23
(b) a clinical diagnosis of a depressive disorder, depressive episode
or depression not otherwise specified;
(c) a diagnosis of depression using an established cut-off point on
a validated rating scale, such as a score of ≥ 16 on the Center
for Epidemiological Studies – Depression scale or ≥ 8 on the
Geriatric Depression Scale. 24,25

For RCTs that enrolled patients with depression our secondary
outcome was change in depressive symptoms using a validated
rating scale. This secondary outcome was not used for RCTs
that enrolled non-depressed participants or other study designs
because it was not meaningful in those contexts.

Study selection and data abstraction
Two authors (R.A. and Z.S.) independently reviewed all titles
and abstracts identified by the search. Articles were selected for
full-text review if inclusion criteria were met or if either reviewer
considered them potentially relevant. Disagreements were resolved
by discussion between the two reviewers, and a third author
(S.M.) was available to determine eligibility if consensus could
not be reached. Initial agreement was assessed using an
unweighted k value. Data were extracted by two authors (R.A.
and Z.S.) independently using a form developed for this review,
with disagreements resolved as above. We attempted to contact
study authors for additional or missing information when needed.

Assessment of risk of bias
Two reviewers (R.A. and Z.S.) independently assessed the risk of
bias using a modified Newcastle–Ottawa Scale (see online
supplement DS3). 26 In observational studies one of the main
sources of bias is confounding. Known confounders can be
statistically adjusted, but unknown confounders may still result
in bias. It was decided a priori that studies that adjusted for factors
shown elsewhere to affect vitamin D levels (chronic disease, body
mass index, geographical location, season and physical
activity) 27,28 would be considered to have a low risk of bias,
whereas studies that adjusted only for other potential confounders
would have an unclear risk of bias, and any studies that did not adjust
for any confounders would have a high risk of bias. Publication
bias was assessed using funnel plots.

Statistical analysis
Search results were compiled using citation management software
(RefWorks version 2.0; ProQuest, http://www.refworks.com).
Statistical analysis was performed using Review Manager software
(RevMan version 5.1; Cochrane Collaboration, Oxford, UK),
Epi Info version 6.0 (CDC, Atlanta, Georgia, USA) and PASW
Statistics version 18.0 (SPSS, Chicago, Illinois, USA) for Mac.

Case–control studies
The standardised mean difference (SMD) of vitamin D levels
between the participants with depression and the healthy controls
was calculated. An SMD below 0.4 was considered small, 0.4–0.7
moderate and over 0.7 large. 29 Our protocol proposed pooling
SMDs for meta-analysis using a random effects model.

Cross-sectional studies
Our protocol proposed examining adjusted odds ratios (ORs)
of depression for those with or without vitamin D deficiency (as
defined in each study) and the associated 95% confidence
intervals. We planned to pool the adjusted ORs for meta-analysis.
Unfortunately the cross-sectional studies used different reference
categories of vitamin D concentration (either < 50 nmol/l or the
lowest and highest category) and presented data using different
quartiles, tertiles or categories. After protocol development, but
prior to analysing the data, we decided to use the adjusted OR
of depression for the lowest v. highest vitamin D categories
reported. The inverse variance method and random effects model
were used for all meta-analyses. A random effects model was
chosen because we anticipated heterogeneity among studies.
Where ORs were reported for subgroups of patients within a
single study, they were combined into a single OR for our
analysis. 30

Cohort studies
As with the analysis of cross-sectional studies, the variability in
presentation of results of the cohort studies precluded the
calculation of a pooled adjusted OR. We therefore contacted
the authors of all three cohort studies to obtain the number of
depressed participants and the person-years of follow-up in each
category of vitamin D, and requested data using the cut-off point
of 50 nmol/l. This allowed us to calculate hazard rates for each
category, so that we could then account for losses to follow-up
and variable follow-up periods also, by assuming a constant
hazard rate over time, we could pool hazard ratios using a cut-
off point of 50 nmol/l. All authors provided some data, but one
provided only data using the cut-off points of 37.5 nmol/l and
75 nmol/l. 9 We therefore performed a sensitivity analysis using these
two cut-off points in a meta-analysis.

Additionally, we decided to analyse the cohort data using the
highest v. lowest vitamin D categories in order to use the adjusted
results and take confounding into account. For this analysis the
adjusted hazard ratios were used; the adjusted OR from one study
was converted first to a relative risk and then to a hazard ratio
(HR). 10 Finally, we performed a third analysis in which we
calculated the increase in the natural logarithm of the hazard rate
(ln(HR)) of depression per 20 nmol/l decrease in vitamin D for
each study. 31 The mid-point of each category of vitamin D was
calculated and half the width of the adjacent category was used
to define the corresponding point for open-ended categories.
The ln(HR) for each category was then regressed on the vitamin
D mid-points (divided by 20) using a linear model, with the data
weighted by the inverse variance of the ln(HR), to generate a
coefficient that represented the change in ln(HR) per 20 nmol/l
decrease in vitamin D and its associated standard error. The
coefficients for each study were then pooled for meta-analysis.

Assessment of heterogeneity
Heterogeneity between the studies was measured using Cochran’s
Q statistic, with a probability value of P < 0.05 (two-tailed)
considered statistically significant. The I² statistic was used to
quantify the degree of heterogeneity and we considered values
below 25% to be low, 25–50% moderate and over 50% high. 32

Subgroup and sensitivity analyses
We planned the following subgroup analyses a priori: gender, age
≥ 65 years, prevalence of vitamin D deficiency, proportion of
participants with a disease known to affect vitamin D, and
adjustment for different confounders. We planned a priori to
perform a sensitivity analysis excluding studies with a high risk
of bias. For the cohort studies we performed a sensitivity analysis
using the cut-off point of 37.5 nmol/l compared with 75 nmol/l for
the one study that did not provide data using our standard cut-off
point of 50 nmol/l. We also performed a sensitivity analysis for the cross-sectional studies excluding one study that had recruited participants aged 15–39 years\(^{33}\) (our inclusion criteria specified adults aged 18 years).

## Results

Our primary search identified 6675 citations (Fig. 1). No additional article or abstract was selected from other sources. After duplicates were removed 5484 citations remained for title and abstract screening. Of these, 35 were identified and retrieved for full-text screening; all were in English. After full text review, one case–control study,\(^ {34}\) three cohort studies,\(^ {9,10,35}\) and ten cross-sectional studies,\(^ {8,11,20,21,30,33,36–39}\) met eligibility criteria and were included (unweighted \(k = 0.75\)). Figure 1 lists the reasons for excluding the other studies.\(^ {19,40–58}\)

### Study characteristics

Baseline information on the case–control, cross-sectional and cohort studies is presented in Tables 1 and 2. There were 31 424 participants in total. All studies were published between 2006 and 2011; study locations included the USA, Europe and East Asia. Seven of the ten cross-sectional studies included older adults.

### Risk of bias in included studies

#### Case–control study

The agreement between the reviewers in assessing the risk of bias for the case–control study across the nine points of the Newcastle–Ottawa Scale was 100%, with both reviewers assigning the same four points. There was potential for selection bias as participants were recruited through advertisements and were all premenopausal women; also, the study did not control for known confounders.

#### Cross-sectional studies

Agreement between the reviewers in assessing the risk of bias in cross-sectional studies was 95%, unweighted \(k = 0.84\). Four studies were thought to be unrepresentative of the general population: Johnson et al included only low-income older adults;\(^ {60}\) Lee et al included only elderly men;\(^ {77}\) and the two studies by Wilkins et al included only elderly participants, half of whom in the 2006 study were purposely selected to have Alzheimer’s disease, and in the 2009 study were purposely selected to include African Americans and European Americans in equal numbers.\(^ {8,39}\) Seven studies received a high risk of bias assignment for assessment of outcome because they used cut-off points on self-reported psychiatric rating scales. Two studies received an unclear risk of bias assignment for using administered surveys, which were felt to have an intermediate risk of bias between a self-report scale and clinician-administered standardised psychiatric interview. All studies adjusted for multiple confounders (online supplement DS4). The funnel plot (online supplement DS5) did not suggest significant publication bias.

#### Cohort studies

Agreement between the reviewers in assessing the risk of bias across cohort studies was 88%, unweighted \(k = 0.61\). Two studies\(^ {6,10}\) were considered unrepresentative of the general population, and the study by May et al was thought to be at high risk of bias for selection of the non-exposed cohort because vitamin D levels were obtained at the discretion of treating physicians,\(^ {2}\) which may have biased whose vitamin D levels were observed. All studies included in this review adjusted for multiple confounders, but May et al did not measure or adjust for physical activity, body mass index or the presence of chronic diseases and therefore received an unclear risk of bias rating. Chan et al and Milaneschi et al used cut-off points on self-report scales to diagnose depression,\(^ {10,35}\) which is less reliable than a clinical diagnosis, and therefore these studies were rated at high risk of bias. Although May et al used a clinical diagnosis of depression using ICD-9 codes, it was not clear whether all participants underwent a clinical assessment or whether record linkage was used; an unclear risk of bias was therefore assigned. May et al presented the average duration of follow-up period but did not otherwise describe loss to follow-up, and therefore this received an unclear rating. Because there were only three cohort studies the funnel plot was uninformative.\(^ {79}\) Further information on the risk of bias assessments is included in online supplement DS5.

### Outcome evaluation and meta-analysis

A summary of the results from the cross-sectional and cohort meta-analyses including subgroup and sensitivity analyses is presented in Table 3. Three cross-sectional studies did not report ORs, and the authors of these studies were contacted.\(^ {20,36,39}\) One author replied and the OR provided was included in the meta-analysis;\(^ {36}\) an unadjusted OR and 95% CI were calculated.

---

### Table 1: Baseline information on the cross-sectional studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Participants</th>
<th>Age Range</th>
<th>Setting</th>
<th>Country/Region</th>
<th>Method of Selection</th>
<th>Inclusion Criteria</th>
<th>Risk of Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson et al</td>
<td>214</td>
<td>65–85 years</td>
<td>Community</td>
<td>USA</td>
<td>Record linkage</td>
<td>Adults aged 65+ with &lt; 600 nmol/l vitamin D</td>
<td>High</td>
</tr>
<tr>
<td>Lee et al</td>
<td>300</td>
<td>65–85 years</td>
<td>Community</td>
<td>USA</td>
<td>Random sampling</td>
<td>Adults aged 65+</td>
<td>High</td>
</tr>
<tr>
<td>Wilkins et al</td>
<td>150</td>
<td>65–85 years</td>
<td>Community</td>
<td>USA</td>
<td>Record linkage</td>
<td>Adults aged 65+ with &lt; 600 nmol/l vitamin D</td>
<td>High</td>
</tr>
</tbody>
</table>

---

### Table 2: Baseline information on the cohort studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Participants</th>
<th>Follow-up</th>
<th>Setting</th>
<th>Country/Region</th>
<th>Method of Selection</th>
<th>Inclusion Criteria</th>
<th>Risk of Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson et al</td>
<td>500</td>
<td>1 year</td>
<td>Community</td>
<td>USA</td>
<td>Random sampling</td>
<td>Adults aged 65+</td>
<td>High</td>
</tr>
<tr>
<td>Lee et al</td>
<td>300</td>
<td>1 year</td>
<td>Community</td>
<td>USA</td>
<td>Random sampling</td>
<td>Adults aged 65+</td>
<td>High</td>
</tr>
<tr>
<td>Wilkins et al</td>
<td>150</td>
<td>1 year</td>
<td>Community</td>
<td>USA</td>
<td>Record linkage</td>
<td>Adults aged 65+ with &lt; 600 nmol/l vitamin D</td>
<td>High</td>
</tr>
</tbody>
</table>

---

### Fig. 1 Study selection process.
for another study using data provided in the paper and Epi Info version 6.0,39 but the third study could not be included.39

Case–control study
One study compared vitamin D levels in women with depression and healthy controls.34 The mean difference between the groups was 17.5 nmol/l (P = 0.002), with an SMD of 0.60 (95% CI 0.23–0.97). This represented a moderate difference,29 which was also clinically significant. Meta-analysis could not be performed as only one study met our inclusion criteria.

Cross-sectional studies
The cross-sectional studies measured rates of depression and vitamin D in a population at a single point in time to determine whether there was an association between depression and vitamin D levels. Nine studies reported on depression for the lowest tertile of vitamin D categories, with a pooled OR of 1.31, 95% CI 1.00–1.71 (Fig. 2). There was substantial heterogeneity between studies (I² = 54%, χ² = 17.24, P = 0.03). The only subgroup analysis that could be performed was of studies that had an average sample age of 65 years (online supplement DS5). When these studies were combined there was an increased – although non-significant – odds of depression with low vitamin D (OR = 1.54, 95% CI 1.00–2.40). A sensitivity analysis excluding the study by Ganji et al (online supplement DS6) had a minimal effect on our summary estimate (OR = 1.34, 95% CI 0.99–1.83, I² = 59%, χ² = 17.16, P = 0.02).33

Cohort studies
Three studies measured vitamin D levels at baseline in non-depressed individuals and followed them over time to determine whether vitamin D levels were associated with a risk of developing

---

Table 1 Characteristics of included studies: case–control and cross-sectional studies

<table>
<thead>
<tr>
<th>Study, year</th>
<th>Country</th>
<th>Population</th>
<th>Mean age, years</th>
<th>n</th>
<th>Diagnosis of depression</th>
<th>Categories of vitamin D, nmol/l</th>
<th>Measurement of vitamin D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case–control studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eskandari (2007)38</td>
<td>USA</td>
<td>Women aged 21–45 years</td>
<td>35</td>
<td>133</td>
<td>SCID</td>
<td>NA</td>
<td>CPBA</td>
</tr>
<tr>
<td>Cross-sectional studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ganji (2010)33</td>
<td>USA</td>
<td>Men and women aged 15–39 years</td>
<td>27.5</td>
<td>7970</td>
<td>DIS</td>
<td>&lt;50, 50–75, &gt;75</td>
<td>RIA</td>
</tr>
<tr>
<td>Hoogenrijk (2008)36</td>
<td>The Netherlands</td>
<td>Men and women aged 65–95 years</td>
<td>75.1</td>
<td>1282</td>
<td>Score ≥16 on CES-D</td>
<td>Cut-off point 50</td>
<td>CPBA</td>
</tr>
<tr>
<td>Johnson (2008)30</td>
<td>USA</td>
<td>Older adults</td>
<td>77</td>
<td>158</td>
<td>Score ≥11 on GDS-10</td>
<td>&lt;25, 25–50, &gt;50</td>
<td>RIA</td>
</tr>
<tr>
<td>Lee (2011)37</td>
<td>USA</td>
<td>Men aged 40–79 years</td>
<td>59.7</td>
<td>3151</td>
<td>Score ≥14 BDI-II</td>
<td>&lt;25, 25–49.9, 50–74.9, &gt;75</td>
<td>RIA</td>
</tr>
<tr>
<td>Nanri (2009)39</td>
<td>Japan</td>
<td>Men and women aged 21–67 years</td>
<td>43.4</td>
<td>527</td>
<td>Score ≥16 on CES-D</td>
<td>Quartiles (medians 53.75, 64.75, 72.5, 82)</td>
<td>CPBA</td>
</tr>
<tr>
<td>Pan (2009)31</td>
<td>China</td>
<td>Men and women aged 50–70 years</td>
<td>NR</td>
<td>3262</td>
<td>Score ≥16 on CES-D</td>
<td>Quartiles (means 26.1, 41.1, 65.1)</td>
<td>RIA</td>
</tr>
<tr>
<td>Stewart (2010)38</td>
<td>UK</td>
<td>Men and women aged &gt;/= 65 years</td>
<td>73.7</td>
<td>2070</td>
<td>Score ≥3 on GDS-10</td>
<td>&lt;25, &lt;50, &lt;75</td>
<td>RIA</td>
</tr>
<tr>
<td>Wilkins (2006)8</td>
<td>USA</td>
<td>Men and women aged &gt;/= 60 years</td>
<td>74.5</td>
<td>80</td>
<td>Depression Symptoms Inventory</td>
<td>&lt;25, 25–50, &gt;50</td>
<td>RIA</td>
</tr>
<tr>
<td>Wilkins (2009)39</td>
<td>USA</td>
<td>Men and women aged &gt;/= 55 years</td>
<td>74.99</td>
<td>60</td>
<td>Depressive Features Inventory</td>
<td>Cut-off point 50</td>
<td>CPBA</td>
</tr>
<tr>
<td>Zhao (2010)37</td>
<td>USA</td>
<td>Men and women aged &gt;/= 20 years</td>
<td>NR</td>
<td>3916</td>
<td>Score ≥10 on PHQ-9</td>
<td>&lt;37.5, 37.5–50, 50–65, &gt;65</td>
<td>RIA</td>
</tr>
</tbody>
</table>

Total cross-sectional studies 22 476

BDI, Beck Depression Inventory; CES-D, Center for Epidemiological Studies – Depression scale; CPBA, competitive protein binding assay; DIS, Diagnostic Interview Schedule; GDS, Geriatric Depression Scale; NA, not applicable; NR, not reported; PHQ, Patient Health Questionnaire; RIA, radioimmunoassay; SCID, Structured Clinical Interview for DSM-IV.

Table 2 Characteristics of included studies: cohort studies

<table>
<thead>
<tr>
<th>Study, year</th>
<th>Country</th>
<th>Population</th>
<th>Mean age, years</th>
<th>n</th>
<th>Diagnosis of depression</th>
<th>Categories of vitamin D, nmol/l</th>
<th>Measurement of vitamin D</th>
<th>Loss to follow-up, %</th>
<th>Length of follow-up, years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chan (2011)30</td>
<td>China</td>
<td>Men aged &gt;/= 65 years</td>
<td>72.5</td>
<td>801</td>
<td>Score 8 on GDS</td>
<td>Quartiles (&lt;63, 64–76, 77–91, &gt;92) and categories (&lt;30, 30–74, 75–99, &gt;100)</td>
<td>RIA</td>
<td>21</td>
<td>4</td>
</tr>
<tr>
<td>May (2010)9</td>
<td>USA</td>
<td>Cardiovascular patients aged &gt;/= 50 years</td>
<td>73.1</td>
<td>7358</td>
<td>Clinical diagnosis</td>
<td>Categories (&lt;37.5, 37.5–75, 75–125, &gt;125)</td>
<td>CIA</td>
<td>NR4</td>
<td>10</td>
</tr>
<tr>
<td>Milanesci (2010)39</td>
<td>Italy</td>
<td>Men and women aged &gt;/= 65 years</td>
<td>74.4</td>
<td>656</td>
<td>Score ≥16 on CES-D</td>
<td>Tertiles (&lt;31.7, 31.7–53.9, &gt;53.9) and cut-off point (&lt;50 or ≥50)</td>
<td>RIA</td>
<td>3</td>
<td>6</td>
</tr>
</tbody>
</table>

Total cohort studies 8815

CIA, chemiluminescent immunoassay; CES-D, Center for Epidemiological Studies – Depression scale; GDS, Geriatric Depression Scale; NR, not reported; RIA, radioimmunoassay.

a. Most of cohort (71%) “not evaluable” at 500 days.

b. Mean follow-up period.
depression. There was a statistically significant increased risk of depression with low vitamin D (HR = 2.21, 95% CI 1.40–3.49) with non-significant heterogeneity ($I^2 = 21\%$, $w^2 = 2.52$, $P = 0.28$) when the HRs for depression for the lowest v. highest vitamin D categories in the three cohort studies were pooled (Fig. 3). The change in the ln(HR) of depression per 20 nmol/l change in vitamin D level was calculated for each study and pooled. There was a non-significant decreased ln(HR) of depression for each 20 nmol/l increase in vitamin D ($β = −0.19$, 95% CI $−0.41$ to $0.04$; Fig. 4).

The HRs of depression for those with and without vitamin D levels below 50 nmol/l from the studies by Chan et al and
vitamin D deficiency at levels below 50 nmol/l cannot be reliably
depression with vitamin D deficiency. Therefore, the effect of
(cut-off point 37.5 nmol/l), the HR suggests a decreased risk of
However, if this group is included in the normal vitamin D group
in the vitamin D deficient group (cut-off point 75 nmol/l), the HR
suggests an increased risk of depression with vitamin D deficiency.

The overall HR in this analysis was not significant (HR = 1.04, 95%
CI 0.59–1.86). In the second analysis using cut-off points, the HR of
depression for vitamin D below 50 nmol/l was 1.31 (95% CI 1.00–1.71,
P = 0.05). Limiting the analysis to studies with an average participant age
of 65 years or over did not substantially change the overall

Our systematic review identified one case–control study, ten cross-
sectional studies and three cohort studies investigating the
association between depression and vitamin D deficiency, but
no randomised controlled trial. The single case–control study
showed a moderate difference in vitamin D levels between women
with depression and healthy controls. Meta-analysis of the cross-
sectional studies demonstrated an increased but non-significant
odds of depression for the lowest compared with the highest
vitamin D categories (OR = 1.31, 95% CI 1.00–1.71, P = 0.05).

Milaneschi et al were pooled with the HR of depression for vitamin
D below 37.5 nmol/l from the study by May et al (Fig. 5). The
overall HR in this analysis was not significant (HR = 1.04, 95% CI
0.59–1.86). In the second analysis using cut-off points, the HR of
depression for vitamin D below 37.5 nmol/l from the May et al study was pooled with the other results (Fig. 6). This also gave a
non-significant HR of 1.31 (95% CI 0.97–1.77). Interestingly, using
the cut-off point of 75 nmol/l compared with 37.5 nmol/l changed
the direction of the effect in this study. This appears to result from
the highest hazard rate, and largest number of participants, being in the 37.5–75 nmol/l category. Therefore, if this group is included
in the vitamin D deficient group (cut-off point 75 nmol/l), the HR
suggests an increased risk of depression with vitamin D deficiency.
However, if this group is included in the normal vitamin D group
(cut-off point 37.5 nmol/l), the HR suggests a decreased risk of
depression with vitamin D deficiency. Therefore, the effect of
vitamin D deficiency at levels below 50 nmol/l cannot be reliably
determined from this study.

No planned subgroup or sensitivity analysis could be performed because of insufficiently reported data and inability to obtain such data from authors.

**Discussion**

Our systematic review identified one case–control study, ten cross-
sectional studies and three cohort studies investigating the
association between depression and vitamin D deficiency, but
no randomised controlled trial. The single case–control study
showed a moderate difference in vitamin D levels between women
with depression and healthy controls. Meta-analysis of the cross-
sectional studies demonstrated an increased but non-significant
odds of depression for the lowest compared with the highest
vitamin D categories (OR = 1.31, 95% CI 1.00–1.71, P = 0.05).

Limiting the analysis to studies with an average participant age
of 65 years or over did not substantially change the overall

---

**Table 1**: Hazard Ratio (HR) of Depression with Vitamin D Deficiency using cut-off points of 50 nmol/l and 37.5 nmol/l (see caption to Fig. 3 for explanation of symbols).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>log (HR)</th>
<th>s.e.</th>
<th>Weight, %</th>
<th>Hazard Ratio</th>
<th>Hazard Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chan (2011)</td>
<td>-0.3014</td>
<td>0.17883</td>
<td>31.0</td>
<td>0.74 (0.52, 1.05)</td>
<td></td>
</tr>
<tr>
<td>May (2010)</td>
<td>-0.1851</td>
<td>0.03034</td>
<td>34.9</td>
<td>0.83 (0.78, 0.88)</td>
<td></td>
</tr>
<tr>
<td>Milaneschi (2010)</td>
<td>0.5905</td>
<td>0.08063</td>
<td>34.1</td>
<td>1.80 (1.54, 2.11)</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td></td>
<td></td>
<td>100.0</td>
<td>1.04 (0.59, 1.86)</td>
<td></td>
</tr>
</tbody>
</table>

**Fig. 4**: Cohort studies: forest plot of the change in the natural logarithm of the hazard rate ln(HR) of depression per 20 nmol/l change in vitamin D using trend estimation. Squares to the right of the vertical line indicate a positive slope or increased risk of depression with increased vitamin D levels, whereas squares to the left indicate a negative slope or decreased risk of depression with increased vitamin D levels. Horizontal lines represent the associated 95% confidence intervals and the diamond represents the overall change in ln(HR) of depression per 20 nmol/l change in vitamin D from the meta-analysis and the corresponding 95% confidence interval.

**Fig. 5**: Cohort studies: forest plot of the hazard ratios (HR) of depression with vitamin D deficiency using cut-off points of 50 nmol/l and 37.5 nmol/l (see caption to Fig. 3 for explanation of symbols).

**Fig. 6**: Cohort studies: forest plot of the hazard ratios (HR) of depression with vitamin D deficiency using cut-off points of 50 nmol/l and 75 nmol/l (see caption to Fig. 3 for explanation of symbols).
estimate or statistical significance. There was considerable variability in the vitamin D categories used in the cohort studies, and therefore three different meta-analyses were performed. Our pooled HR of the lowest compared with the highest vitamin D categories in the three cohort studies showed a significantly increased HR of depression with low vitamin D levels (HR = 2.21, 95% CI 1.40–3.49, P < 0.001). The pooled change in ln(HR) of depression per 20 nmol/l change in vitamin D level across the three cohort studies also showed an increased hazard of depression with decreasing vitamin D concentration, although this was not significant (β = −0.19, 95% CI −0.41 to 0.04, P = 0.1).

Finally, we analysed the data using different cut-off points as provided in the studies, which yielded different but non-significant pooled HR: 1.04 (95% CI 0.59–1.86) v. 1.31 (95% CI 0.97–1.77). Overall, the summary estimates of all analyses suggest a relationship between vitamin D and depression, and all but one were close to being statistically significant.

Strengths and limitations
To the best of our knowledge this is the first systematic review or meta-analysis that has analysed the relationship between vitamin D deficiency and depression. We performed a transparent and methodologically rigorous systematic review of the literature. We developed a comprehensive search to identify articles and assessed their eligibility, extracted data and assessed risk of bias in each study in duplicate with a good level of agreement. Our protocol was developed a priori and any post hoc analyses were clearly identified. A particular strength was the method used and extensive analyses performed in an attempt to present the data in a uniform and consistent manner to allow for comparison and combination. We were also successful in obtaining supplemental information from several authors, which allowed us to include the majority of studies.

There are several limitations to our systematic review. As, at the time of our review, there was no RCT of vitamin D for depression our review was restricted to observational studies, which usually yield lower-quality evidence than RCTs. Reverse causality, in which patients with depression have less exposure to the sun and therefore lower vitamin D levels, cannot be ruled out in the cross-sectional studies. In addition there were potential biases across all study designs. Several cross-sectional studies had unrepresentative samples, used self-reports of depression and had small sample sizes. The study results were generally consistent, with the exception of those from Pan et al who reported a decreased odds of depression with low vitamin D.11 This was the only cross-sectional study conducted in China, and geographical differences in the nature and prevalence of vitamin D deficiency and depression might explain their discrepant findings. One small study could not be included in the quantitative analysis as insufficient information was available; it found an increased prevalence of depression with vitamin D deficiency20 and therefore it is unlikely that it would have significantly affected our findings.

Most studies adjusted for multiple confounders; however, unadjusted data were used to generate an odds ratio for one study where an adjusted OR was not provided.19 All the cohort studies had problems with bias and the largest one had a high risk of bias. Publication bias could not be ruled out, and it is possible that additional cohort studies have measured vitamin D and depression but not reported negative results. The majority of the meta-analyses of the cross-sectional studies and cohort studies had significant heterogeneity and lacked precision. Studies used variable definitions of vitamin D deficiency, and therefore we performed analyses using the lowest v. highest vitamin D categories and different cut-off points rather than adhering to a strict definition of deficiency. As a result of these limitations the overall quality of the evidence from each study is low and therefore some uncertainty remains about the true association between vitamin D deficiency and depression.

Implications of the study
The importance of vitamin D to many brain processes including neuroimmunomodulation and neuroplasticity suggests that it might have a role in psychiatric illness such as depression. The biological plausibility of the association between vitamin D and depressive illness has been strengthened by the identification of vitamin D receptors in areas of the brain implicated in depression,4 the detection of vitamin D response elements in the promoter regions of serotonin genes,60 and demonstration of interactions between vitamin D receptors and glucocorticoid receptors in the hippocampus.61 Given the high prevalence of both vitamin D deficiency and depression, an association between these two conditions would have significant public health implications, particularly as supplementation with vitamin D is cost-effective and without significant adverse effects. The observational studies to date provide some evidence for a relationship between vitamin D deficiency and depression, but RCTs are urgently needed to determine whether vitamin D can prevent and treat depression.

References

Funding

There was no dedicated funding to support this study. R.A. is supported by an Ontario Mental Health Foundation Research Training Fellowship Award, I.S. is supported by Hamilton Health Sciences New Investigator Fund and S.M. is supported by a Canadian Institutes of Health Research New Investigator Award.

Acknowledgements

We thank Neera Bhatnager, librarian, McMaster University Health Sciences Library, for her assistance in developing the search strategy and Peter Szatmari for his critical review of the manuscript.

Anglin et al

Ganji V, Milone C, Cody MM, McCarty F, Wang YT. Serum vitamin D
Orme JG, Reis J, Herz EJ. Factorial and discriminant validity of the Center for
23
13
12
11
Pan A, Lu L, Franco OH, Yu Z, Li H, Lin X. Association between depressive
10
9
18
17
Rosen CJ. Clinical practice. Vitamin D insufficiency.
Greenland S, Longnecker MP. Methods for trend estimation from
31
29
Johnson MA, Fischer JG, Park S. Vitamin D deficiency and insufficiency in the
27
26
24
23
19
18
17
16
15
14
13
12
11
Bloomfield CD, Moore CB, Corbett C, Bindler R. Vitamin D and depressive
10
9
10
9
8
7
6
5
5
4
4
3
3
2
Jorde R, Waterloo K, Saleh F, Haug E, Svartberg J. Neuropsychological function in relation to serum parathyroid hormone and serum 25-
2
hydroxyvitamin D levels. The Tromso study. J Neurol 2006; 253: 444–70.
2
1
1
0
Supplement DS1  Search strategy

**EMBASE Search Strategy**

1 exp DEPRESSION/
2 exp major depression/
3 exp mood disorder/
4 exp MOOD/
5 exp AFFECT/
6 (depression or depressive disorder* or mood disorder* or mental disorder* or affect or affective symptom* or affective disorder* or major depress* or unipolar depress* or psychiatric symptom* or mood).mp
7 1 or 2 or 3 or 4 or 5 or 6
8 exp vitamin D/
9 exp vitamin D deficiency/
10 exp vitamin blood level/
11 exp cholecalciferol/
12 exp ergocalciferol/
13 (vitamin D or vitamin D deficien* or hydroxycholecalciferol* or 25-hydroxyvitamin D or cholecalciferol* or ergocalciferol* or calcifediol* or calcitriol* or hydroxyvitamin*).mp
14 8 or 9 or 10 or 11 or 12 or 13
15 7 and 14
16 Nonhuman/ not human/
17 15 not 16

**MEDLINE and Pubmed Search Strategy**

1 exp Depression/
2 exp Mood Disorders/
3 exp Depressive Disorder/
4 exp Affect/
5 exp Affective Symptoms/
6 (depression or depressive disorder* or mood disorder* or mental disorder* or affect or affective symptom* or affective disorder* or major depress* or unipolar depress* or psychiatric symptom* or mood).mp
7 1 or 2 or 3 or 4 or 5 or 6
8 exp Vitamin D/
9 exp Vitamin D Deficiency/
10 exp cholecalciferol/
11 exp ergocalciferol/
12 exp Hydroxycholecalciferols/
13 (vitamin D or vitamin D deficien* or hydroxycholecalciferol* or 25-hydroxyvitamin D or cholecalciferol* or ergocalciferol* or calcifediol* or calcitriol* or hydroxyvitamin*).mp
14 8 or 9 or 10 or 11 or 12 or 13
15 7 and 14
16 Animals/ not humans/
17 15 not 16
PsycINFO Search Strategy

1 exp Major Depression/
2 exp Psychiatric Symptoms/
3 exp Emotional States/
4 exp Mental Disorders/
5 exp Affective Disorders/
6 (depression or depressive disorder* or mood disorder* or mental disorder* or affect or affective symptom* or affective disorder* or major depress* or unipolar depress* or psychiatric symptom* or mood).mp
7 1 or 2 or 3 or 4 or 5 or 6
8 exp Vitamins/
9 exp Vitamin Deficiency Disorders/
10 (vitamin D or vitamin D deficien* or hydroxycholecalciferol* or 25-hydroxyvitamin D or cholecalciferol* or ergocalciferol* or calcifediol* or calcitriol* or hydroxyvitamin*).mp
11 8 or 9 or 10
13 7 and 11

AMED Search Strategy

1 exp Depression/
2 exp Depressive Disorder/
3 exp Affective disorders/
4 (depression or depressive disorder* or mood disorder* or mental disorder* or affect or affective symptom* or affective disorder* or major depress* or unipolar depress* or psychiatric symptom* or mood).mp
5 1 or 2 or 3 or 4
6 exp Vitamin D/
7 exp cholecalciferol/
8 exp Vitamins/
9 exp Dietary supplements/
10 (vitamin D or vitamin D deficien* or hydroxycholecalciferol* or 25-hydroxyvitamin D or cholecalciferol* or ergocalciferol* or calcifediol* or calcitriol* or hydroxyvitamin*).mp
11 6 or 7 or 8 or 9 or 10
12 5 and 11

CINAHL Search Strategy

S1 Depression +
S2 Affective Disorders +
S3 Mental Disorders + OR Mental Disorders, Chronic
S4 depression or depressive disorder* or mood disorder* or mental disorder* or affect or affective symptom* or affective disorder* or major depress* or unipolar depress* or psychiatric symptom* or mood
S5 Vitamin D + OR Vitamin D Deficiency + OR Cholecalciferol OR Ergocalciferols
S6 vitamin D or vitamin D deficien* or hydroxycholecalciferol* or 25-hydroxyvitamin D or cholecalciferol* or ergocalciferol* or calcifediol* or calcitriol* or hydroxyvitamin*
S7 S1 or S2 or S3 or S4
S8 S5 or S6
S9 S7 and S8
Supplement DS2  Detailed eligibility criteria

The following study designs were eligible for inclusion:
(1) (RCTs) that enrolled adults (age ≥ 18) with depression (major depressive disorder, depressive episode or depression NOS) and reported depression as the outcome of interest as defined below or depressive symptoms measured using a validated scale.
(2) RCTs that enrolled any adults and reported depression outcomes of interest.
(3) case- control studies that compared adults with depression to healthy controls and reported vitamin D measurements.
(4) cross-sectional studies that measured vitamin D levels in adults and reported depression outcomes of interest associated with vitamin D deficiency (as defined by each study, Tables 1 & 2) compared to those with normal vitamin D.
(5) cohort studies that measured serum vitamin D levels in adults and reported the rates of depression as the outcome of interest at follow-up for those with vitamin D deficiency compared to those with normal vitamin D.
### Modified Newcastle–Ottawa Scales

#### Newcastle-Ottawa Scale for case–control studies data abstraction form

<table>
<thead>
<tr>
<th>Bias</th>
<th>Case control</th>
<th>* High Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Selection</strong> (max 4*)</td>
<td>Is the case definition adequate?</td>
<td>Yes, with independent validation</td>
</tr>
<tr>
<td></td>
<td>Consecutive or obviously representative series of cases</td>
<td>Yes, eg record linkage or based on self report</td>
</tr>
<tr>
<td></td>
<td>Potential for selection bias or not stated</td>
<td>No description</td>
</tr>
<tr>
<td></td>
<td>Representativeness of the cases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Selection of controls</td>
<td>Community controls</td>
</tr>
<tr>
<td></td>
<td>Definition of controls</td>
<td>Hospital controls</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No description</td>
</tr>
<tr>
<td><strong>Comparability</strong> (max 2*)</td>
<td>Cases and controls on the basis of the design or analysis</td>
<td>Study controls for important factor</td>
</tr>
<tr>
<td></td>
<td>Study controls for a 2nd important factor</td>
<td>No control for any important factor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Exposure</strong> (max 3*)</td>
<td>Ascertainment of exposure</td>
<td>Secure record</td>
</tr>
<tr>
<td></td>
<td>Non-response rate</td>
<td>Interview not blinded to case/control status</td>
</tr>
<tr>
<td></td>
<td>Same method of ascertainment for cases</td>
<td>Written self report or medical record only</td>
</tr>
<tr>
<td></td>
<td>Non-respondents described</td>
<td>Rate different and no designation</td>
</tr>
</tbody>
</table>

* High Quality: No description
<table>
<thead>
<tr>
<th>Bias</th>
<th>Cohort</th>
<th>* High Quality</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Selection</strong></td>
<td>Representativeness of exposed cohort (Vitamin D deficient and insufficient participants)</td>
<td>Truly representative of the general population</td>
<td></td>
</tr>
<tr>
<td>(max 4*)</td>
<td></td>
<td>Somewhat representative of general population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Selection of non exposed cohort (adequate vitamin D levels)</td>
<td>Drawn from the same community as the exposed cohort</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drawn from a different source</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ascertainment of exposure</td>
<td>Reliable measurement of vitamin D</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reported intake of vitamin D</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Demonstration that outcome of interest was not present at start of study</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Comparability of cohorts on basis of design or analysis</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>(max 2*)</td>
<td></td>
<td>Study controls for important factor (chronic diseases, BMI or physical activity)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Study controls for any additional factor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assessment of outcome</td>
<td>Independent blind assessment</td>
<td></td>
</tr>
<tr>
<td>(max 3*)</td>
<td></td>
<td>Record linkage</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Was follow-up long enough for outcome to occur</td>
<td>Yes (&gt;=3 months)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adequacy of follow up of cohorts</td>
<td>Complete follow up-all subjects accounted</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Subjects lost to follow up unlikely to introduce bias – small # lost (&lt;20%) or description provided of lost</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follow up rate &gt;80% and no description of the lost</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>No statement</td>
<td></td>
</tr>
<tr>
<td>Bias</td>
<td>Cross-Sectional Study</td>
<td>* High Quality</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Selection</strong></td>
<td>Representativeness of exposed cohort (Vitamin D deficient participants)</td>
<td>□ Truly representative of the general population</td>
<td></td>
</tr>
<tr>
<td>(max 3*)</td>
<td></td>
<td>□ Somewhat representative of general population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Selection of non exposed cohort (adequate vitamin D levels)</td>
<td>□ Drawn from the same community as the exposed cohort</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ascertainment of exposure (Vitamin D measurement)</td>
<td>□ Secure record (reliable measurement of vitamin D)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Demonstration that outcome of interest was not present at start of study</td>
<td>□Reported intake of vitamin D</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>□ N/A</td>
<td></td>
</tr>
<tr>
<td><strong>Comparability</strong></td>
<td>Comparability of cohorts on basis of design or analysis</td>
<td>□ Study controls for chronic diseases or other important factor</td>
<td></td>
</tr>
<tr>
<td>(max 2*)</td>
<td></td>
<td>□No control for any important factors</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>□ Study controls for any additional factor</td>
<td></td>
</tr>
<tr>
<td><strong>Outcome</strong></td>
<td>Assessment of outcome (depression)</td>
<td>□ Independent blind assessment</td>
<td></td>
</tr>
<tr>
<td>(max 1*)</td>
<td>Was follow-up long enough for outcome to occur</td>
<td>□ Self report</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adequacy of follow up of cohorts</td>
<td>□N/A</td>
<td></td>
</tr>
</tbody>
</table>
**Supplement DS4**  Adjustment for potential confounding variables for analyses across included studies

<table>
<thead>
<tr>
<th>CASE-CONTROL STUDIES</th>
<th>Study, Year</th>
<th>Adjusted variables</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eskandari, 2007</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CROSS-SECTIONAL STUDIES</th>
<th>Study, Year</th>
<th>Adjusted variables</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ganji, 2010</td>
<td>Age, sex, race/ethnicity, geographical location, urbanization, vitamin/mineral supplement use, prescription medication use, poverty income ratio, BMI, serum creatinine</td>
<td></td>
</tr>
<tr>
<td>Hoogendijk, 2008</td>
<td>Age, sex, BMI, smoking, chronic conditions</td>
<td></td>
</tr>
<tr>
<td>Johnson, 2008</td>
<td>No OR provided, study adjusted for demographic characteristics, sunlight exposure, supplemental intake of vitamin D, milk intake</td>
<td></td>
</tr>
<tr>
<td>Lee, 2010</td>
<td>Age, center, smoking, physical activity, alcohol, BMI, life events, psychotropic drugs and morbidities</td>
<td></td>
</tr>
<tr>
<td>Nanri, 2009</td>
<td>Age, sex, BMI, job position, marital status, alcohol, folate intake</td>
<td></td>
</tr>
<tr>
<td>Pan, 2009</td>
<td>Age, sex, urban/rural, BMI, physical activity, smoking status, number of chronic diseases, social activity level, marital status, household income, geographical location</td>
<td></td>
</tr>
<tr>
<td>Stewart, 2010</td>
<td>Age, sex, social class, season, vitamin D supplementation, smoking, BMI, long-standing illness, subjective general health</td>
<td></td>
</tr>
<tr>
<td>Wilkins, 2006</td>
<td>Age, ethnicity, sex, season</td>
<td></td>
</tr>
<tr>
<td>Wilkins, 2009</td>
<td>Unadjusted OR calculated, study adjusted for SBT score, PPT score, BMD, age, race</td>
<td></td>
</tr>
<tr>
<td>Zhao, 2010</td>
<td>Age, sex, ethnicity, education, marital status, BMI, serum creatinine, physical activity, alcohol, number of chronic diseases</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COHORT STUDIES</th>
<th>Study, Year</th>
<th>Adjusted variables</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chan, 2011</td>
<td>Age, BMI, education, PASE, number of ADLs, DQI, smoking status, alcohol use, season of measurement, number of chronic diseases, CSI-D score and serum (ln) PTH concentration</td>
<td></td>
</tr>
<tr>
<td>May, 2010</td>
<td>Age, sex, diabetes, season, PTH, hypertension, coronary artery disease, prior MI, heart failure, prior fracture, renal failure</td>
<td></td>
</tr>
<tr>
<td>Milaneschi, 2010</td>
<td>Age, baseline CES-D, ADL disabilities, use of antidepressants, number of chronic diseases, SPPB, high PTH, season of data collection</td>
<td></td>
</tr>
</tbody>
</table>
Legend: ADL = activities of daily living, BMD = bone mineral density, BMI = body mass index, CES-D = center for epidemiological studies depression scale, CSI-D = community screening instrument for dementia, MMSE = mini mental state examination, PASE = physical activity scale of the elderly, PPT = physical performance test, PTH = parathyroid hormone, SBT = short blessed test, SPPB = short physical performance battery
## Supplement DS5  Risk of bias assessments

**DS5(a) Risk of bias summary for cross-sectional studies: review authors' judgments about each risk of bias item for each included study using the Newcastle-Ottawa Scale\(^{26}\)**

<table>
<thead>
<tr>
<th>Study</th>
<th>Representativeness of exposed cohort</th>
<th>Selection of non-exposed cohort</th>
<th>Ascertainment of exposure</th>
<th>Comparability of cohorts on basis of design or analysis (2 pts)</th>
<th>Assessment of outcome</th>
<th>TOTAL POINTS / 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ganji, 2010</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Hoogendijk, 2008</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Johnson, 2008</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Lee, 2011</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Nanri, 2009</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Pan, 2009</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Stewart, 2010</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Wilkins, 2006</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Wilkins, 2009</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Zhao, 2010</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>
**DS5(b)** Funnel plot to look for publication bias for cross-sectional studies of the association between vitamin D and depression
**DS5(c) Risk of bias summary for cohort studies: review authors’ judgments about each risk of bias item for each included study using the Newcastle-Ottawa Scale**

<table>
<thead>
<tr>
<th></th>
<th>Representativeness of exposed cohort</th>
<th>Selection of non-exposed cohort</th>
<th>Ascertainment of exposure</th>
<th>Outcome of interest not present at start of study</th>
<th>Comparability of cohorts on basis of design or analysis (2 pts)</th>
<th>Assessment of outcome</th>
<th>Length of follow-up</th>
<th>Adequacy of follow-up</th>
<th>TOTAL POINTS / 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chan et al, 2011&lt;sup&gt;4&lt;/sup&gt;</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>May et al, 2010&lt;sup&gt;3&lt;/sup&gt;</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Milaneschi et al, 2010&lt;sup&gt;5&lt;/sup&gt;</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>8</td>
</tr>
</tbody>
</table>
Supplement DS6  Subgroup and sensitivity analyses

DS6(a) Cross-sectional studies: forest plot of the OR of depression for the lowest versus highest vitamin D categories for studies of older adults (average age ≥ 65)

Squares to the right of the vertical line indicate that low vitamin D was associated with an increased odds of depression, squares to the left of the vertical line indicate that low vitamin D was associated with a decreased odds of depression. Horizontal lines represent the associated 95% confidence intervals and the diamond represents the overall OR of depression from the meta-analysis and the corresponding 95% confidence interval. * OR provided by Dr. Penninx (personal communication) on July 25, 2011

DS6(b) Cross-sectional studies: forest plot of the OR of depression for the lowest versus highest vitamin D categories excluding Ganji 2010.

Squares to the right of the vertical line indicate that low vitamin D was associated with an increased odds of depression, squares to the left of the vertical line indicate that low vitamin D was associated with a decreased odds of depression. Horizontal lines represent the associated 95% confidence intervals and the diamond represents the overall OR of depression from the meta-analysis and the corresponding 95% confidence interval. * OR provided by Dr. Penninx (personal communication) on July 25, 2011
Vitamin D deficiency and depression in adults: systematic review and meta-analysis
Rebecca E. S. Anglin, Zainab Samaan, Stephen D. Walter and Sarah D. McDonald
Access the most recent version at DOI: 10.1192/bjp.bp.111.106666